These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 22042958)

  • 1. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.
    Perez EA; Suman VJ; Davidson NE; Gralow JR; Kaufman PA; Visscher DW; Chen B; Ingle JN; Dakhil SR; Zujewski J; Moreno-Aspitia A; Pisansky TM; Jenkins RB
    J Clin Oncol; 2011 Dec; 29(34):4491-7. PubMed ID: 22042958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.
    Fountzilas G; Dafni U; Papadimitriou C; Timotheadou E; Gogas H; Eleftheraki AG; Xanthakis I; Christodoulou C; Koutras A; Papandreou CN; Papakostas P; Miliaras S; Markopoulos C; Dimitrakakis C; Korantzopoulos P; Karanikiotis C; Bafaloukos D; Kosmidis P; Samantas E; Varthalitis I; Pavlidis N; Pectasides D; Dimopoulos MA
    BMC Cancer; 2014 Jul; 14():515. PubMed ID: 25026897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
    Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM
    J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
    Perez EA; Romond EH; Suman VJ; Jeong JH; Sledge G; Geyer CE; Martino S; Rastogi P; Gralow J; Swain SM; Winer EP; Colon-Otero G; Davidson NE; Mamounas E; Zujewski JA; Wolmark N
    J Clin Oncol; 2014 Nov; 32(33):3744-52. PubMed ID: 25332249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
    Perez EA; Romond EH; Suman VJ; Jeong JH; Davidson NE; Geyer CE; Martino S; Mamounas EP; Kaufman PA; Wolmark N
    J Clin Oncol; 2011 Sep; 29(25):3366-73. PubMed ID: 21768458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
    Conte P; Frassoldati A; Bisagni G; Brandes AA; Donadio M; Garrone O; Piacentini F; Cavanna L; Giotta F; Aieta M; Gebbia V; Molino A; Musolino A; Ferro A; Maltoni R; Danese S; Zamagni C; Rimanti A; Cagossi K; Russo A; Pronzato P; Giovanardi F; Moretti G; Lombardo L; Schirone A; Beano A; Amaducci L; Bajardi EA; Vicini R; Balduzzi S; D'Amico R; Guarneri V
    Ann Oncol; 2018 Dec; 29(12):2328-2333. PubMed ID: 30219886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
    Romond EH; Perez EA; Bryant J; Suman VJ; Geyer CE; Davidson NE; Tan-Chiu E; Martino S; Paik S; Kaufman PA; Swain SM; Pisansky TM; Fehrenbacher L; Kutteh LA; Vogel VG; Visscher DW; Yothers G; Jenkins RB; Brown AM; Dakhil SR; Mamounas EP; Lingle WL; Klein PM; Ingle JN; Wolmark N
    N Engl J Med; 2005 Oct; 353(16):1673-84. PubMed ID: 16236738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
    D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
    Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
    Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
    J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
    Spielmann M; Roché H; Delozier T; Canon JL; Romieu G; Bourgeois H; Extra JM; Serin D; Kerbrat P; Machiels JP; Lortholary A; Orfeuvre H; Campone M; Hardy-Bessard AC; Coudert B; Maerevoet M; Piot G; Kramar A; Martin AL; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(36):6129-34. PubMed ID: 19917839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
    Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
    Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
    JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
    Chumsri S; Jeter S; Jacobs LK; Nassar H; Armstrong DK; Emens LA; Fetting JH; Lange JR; Riley C; Tsangaris TN; Wolff AC; Zellars R; Zhang Z; Stearns V
    Clin Breast Cancer; 2010 Feb; 10(1):40-5. PubMed ID: 20133257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.
    Pivot X; Fumoleau P; Pierga JY; Delaloge S; Bonnefoi H; Bachelot T; Jouannaud C; Bourgeois H; Rios M; Soulié P; Jacquin JP; Lavau-Denes S; Kerbrat P; Cox D; Faure-Mercier C; Pauporte I; Gligorov J; Curtit E; Henriques J; Paget-Bailly S; Romieu G
    Eur J Cancer; 2017 Aug; 81():151-160. PubMed ID: 28624696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
    Foldi J; Mougalian S; Silber A; Lannin D; Killelea B; Chagpar A; Horowitz N; Frederick C; Rispoli L; Burrello T; Abu-Khalaf M; Sabbath K; Sanft T; Brandt DS; Hofstatter EW; Hatzis C; DiGiovanna MP; Pusztai L
    Breast Cancer Res Treat; 2018 Jun; 169(2):333-340. PubMed ID: 29396664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
    Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
    Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
    Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
    Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
    Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
    Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.
    Advani PP; Ballman KV; Dockter TJ; Colon-Otero G; Perez EA
    J Clin Oncol; 2016 Feb; 34(6):581-7. PubMed ID: 26392097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.